Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment

[1]  R. Hoffman,et al.  Toxicokinetics of hydroxychloroquine following a massive overdose. , 2019, The American journal of emergency medicine.

[2]  D. Yoon,et al.  Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice , 2018, BioMed research international.

[3]  Rahul R Kauthale,et al.  Assessment of temperature‐induced hERG channel blockade variation by drugs , 2017, Journal of applied toxicology : JAT.

[4]  Long Chen,et al.  Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin , 2017, Cardiovascular Toxicology.

[5]  W. Palmer,et al.  Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study , 2016, Drugs - Real World Outcomes.

[6]  J. Alexander,et al.  Cardiovascular risks with azithromycin and other antibacterial drugs. , 2013, The New England journal of medicine.

[7]  C Michael Stein,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[8]  J. Fisher,et al.  Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors , 2007, Journal of Interventional Cardiac Electrophysiology.

[9]  Chih-Chuan Lin,et al.  Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia , 2006, Clinical toxicology.

[10]  R. Trohman,et al.  Polymorphic Ventricular Tachycardia with a Normal QT Interval Following Azithromycin , 2005, Pacing and clinical electrophysiology : PACE.